David Collingridge

Lancet Laboratories

Papers

2

Total Citations

34

H-Index

2

About

David Collingridge is a leading voice in the field of head and neck oncology, with a research career dedicated to improving therapeutic outcomes for patients facing these complex malignancies. His work critically examines the evolving landscape of treatment, balancing the promise of advanced interventions against the realities of patient quality of life. In his highly cited 2016 contribution to the *9th International Conference on Head and Neck Cancer*, Collingridge synthesized cutting-edge findings from a global forum, helping to shape clinical discourse and research priorities. His 2017 paper, "Treating head and neck cancer: for better or for worse?" (15 citations), stands as a thoughtful, provocative analysis of the trade-offs inherent in modern oncology—weighing aggressive therapies against their long-term functional and psychological toll. Through these influential works, Collingridge has not only advanced scientific understanding but also championed a more patient-centered approach to care. His scholarship, cited by peers worldwide, continues to guide clinicians and researchers in navigating the delicate balance between cure and quality of life in head and neck cancer treatment.

Research Focus

Key Achievements

2
H-Index
2
Papers
34
Total Citations
17
Avg Citations/Paper
🏆 Most Cited Paper
9th International Conference on Head and Neck Cancer
19 citations · 2016
📈 Most Prolific Year: 2016 (1 Papers)
🤝 Key Collaborators: 1
🏛 Institutions: Lancet Laboratories

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago